Organicell Regenerative Medicine, Inc.
OCEL · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 13.7% | 5.4% | -3.7% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $1 | $1 | $1 |
| % Margin | 82.5% | 77.7% | 82.5% | 61.1% |
| R&D Expenses | $0 | $0 | $0 | $1 |
| G&A Expenses | $3 | $2 | $2 | $1 |
| SG&A Expenses | $3 | $2 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $3 | $2 | $2 | $2 |
| Operating Income | -$2 | -$1 | -$1 | -$1 |
| % Margin | -158.6% | -121.3% | -115% | -64.3% |
| Other Income/Exp. Net | -$0 | $0 | $0 | $1 |
| Pre-Tax Income | -$2 | -$1 | -$1 | -$0 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$2 | -$1 | -$1 | $0 |
| % Margin | -158.7% | -121.1% | -114% | 34.8% |
| EPS | -0.32 | -0.22 | -0.2 | 0.062 |
| % Growth | -45.5% | -10% | -421.5% | – |
| EPS Diluted | -0.32 | -0.22 | -0.2 | 0.062 |
| Weighted Avg Shares Out | 6 | 6 | 6 | 6 |
| Weighted Avg Shares Out Dil | 6 | 6 | 6 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$2 | -$1 | -$1 | -$1 |
| % Margin | -158.6% | -121.3% | -115% | -73.2% |